Pre-made Mipasetamab benchmark antibody ( Whole mAb, anti-AXL therapeutic antibody, Anti-ARK/UFO/JTK11/Tyro7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-345

Pre-Made Mipasetamab biosimilar, Whole mAb, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mipasetamab Uzoptirine or ADCT-601 ia humanized antibody that binds to human AXL conjugated using Glycoconnect? technology to a linker with a PBD-dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell, where enzymes release the PBD-based payload.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-345-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Mipasetamab biosimilar, Whole mAb, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody
INN Name Mipasetamab
TargetAXL
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommended2021
CompaniesADC Therapeutics
Conditions Approvedna
Conditions ActiveSolid tumours;Advanced or metastatic solid tumours
Conditions Discontinuedna
Development Techna